Tenaya Therapeutics (TNYA) Free Cash Flow (2020 - 2026)
Tenaya Therapeutics' quarterly Free Cash Flow came in at -$19.3 million in Q1 2026, up 16.84% year-on-year from -$16.5 million in Q1 2025, and down 43.76% quarter-over-quarter from -$13.4 million in Q4 2025.
Tenaya Therapeutics has reported Free Cash Flow for 7 years, with the latest figure at -$19.3 million in Q1 2026.
- For the quarter ending Q1 2026, Free Cash Flow rose 16.84% year-over-year to -$19.3 million; the trailing twelve-month figure through Mar 2026 stood at -$64.4 million (up 24.62% YoY), and the FY2025 full-year result was -$68.3 million, up 24.8% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$19.3 million, down from -$13.4 million in the prior quarter.
- The five-year high for Free Cash Flow was -$13.4 million in Q4 2025, with the low at -$43.0 million in Q4 2022.
- Average Free Cash Flow over 5 years is -$23.9 million, with a median of -$23.2 million recorded in 2025.
- Year-over-year, Free Cash Flow plunged 446.31% in 2022 and surged 49.21% in 2023.
- Tracing TNYA's Free Cash Flow over 5 years: stood at -$43.0 million in 2022, then surged by 49.21% to -$21.9 million in 2023, then advanced by 18.02% to -$17.9 million in 2024, then gained by 24.97% to -$13.4 million in 2025, then sank by 43.76% to -$19.3 million in 2026.
- The last three Free Cash Flow figures came in at -$19.3 million (Q1 2026), -$13.4 million (Q4 2025), and -$16.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.29 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 848.30 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 48.67 Mn |
| 10 | Tenaya Therapeutics | 193.57 Mn | 193.57 Mn | - | -19.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.33 Mn |
| Mar 31, 2026 | -19.33 Mn |
| Dec 31, 2025 | -13.45 Mn |
| Dec 31, 2025 | -13.45 Mn |
| Sep 30, 2025 | -16.14 Mn |
| Sep 30, 2025 | -16.14 Mn |
| Jun 30, 2025 | -15.48 Mn |
| Jun 30, 2025 | -15.48 Mn |
| Mar 31, 2025 | -23.25 Mn |
| Mar 31, 2025 | -23.25 Mn |
| Dec 31, 2024 | -17.93 Mn |
| Dec 31, 2024 | -17.93 Mn |
| Sep 30, 2024 | -20.56 Mn |
| Sep 30, 2024 | -20.56 Mn |
| Jun 30, 2024 | -23.71 Mn |
| Jun 30, 2024 | -23.71 Mn |
| Mar 31, 2024 | -28.67 Mn |
| Mar 31, 2024 | -28.67 Mn |
| Dec 31, 2023 | -21.86 Mn |
| Dec 31, 2023 | -21.86 Mn |
| Sep 30, 2023 | -23.90 Mn |
| Sep 30, 2023 | -23.90 Mn |
| Jun 30, 2023 | -25.64 Mn |
| Jun 30, 2023 | -25.64 Mn |
| Mar 31, 2023 | -30.92 Mn |
| Mar 31, 2023 | -30.92 Mn |
| Dec 31, 2022 | -43.05 Mn |
| Dec 31, 2022 | -43.05 Mn |
| Sep 30, 2022 | -24.76 Mn |
| Sep 30, 2022 | -24.76 Mn |
| Jun 30, 2022 | -23.21 Mn |
| Jun 30, 2022 | -23.21 Mn |
| Mar 31, 2022 | -34.04 Mn |
| Mar 31, 2022 | -34.04 Mn |
| Dec 31, 2021 | -7.88 Mn |
| Dec 31, 2021 | -7.88 Mn |
| Sep 30, 2021 | -27.27 Mn |
| Sep 30, 2021 | -27.27 Mn |
| Jun 30, 2021 | -13.52 Mn |
| Jun 30, 2021 | -13.52 Mn |
| Mar 31, 2021 | -16.24 Mn |
| Mar 31, 2021 | -16.24 Mn |
| Dec 31, 2020 | -9.18 Mn |
| Dec 31, 2020 | -9.18 Mn |
| Sep 30, 2020 | -9.70 Mn |
| Sep 30, 2020 | -9.70 Mn |